Leqvio
| Chemical Name | inclisiran |
| Dosage Form | Injection (subcutaneous; 284 mg/1.5 mL) |
| Drug Class | Small interfering RNA directed to proprotein convertase subtilisin kexin type 9 mRNA |
| System | Cardiovascular |
| Company | Novartis |
| Approval Year | 2021 |
Indication
- Indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C).